Rituxan Rheumatoid Arthritis sBLA Filing Expected In Late 2005
Executive Summary
The first supplemental BLA filing for Rituxan for the treatment of rheumatoid arthritis is slated for the fourth quarter of 2005, Roche Medical Science Department Head Guido Magni said
You may also be interested in...
Genentech Plans Avastin/Tarceva Combo Filing; Avastin Warning Hurts Growth
Genentech and OSI Pharmaceuticals will be meeting with FDA early in 2005 to discuss filing plans for Tarceva (erlotinib) in pancreatic cancer
Genentech Plans Avastin/Tarceva Combo Filing; Avastin Warning Hurts Growth
Genentech and OSI Pharmaceuticals will be meeting with FDA early in 2005 to discuss filing plans for Tarceva (erlotinib) in pancreatic cancer
Biogen Idec Highlights Manufacturing Capacity To Attract Partnerships
Biogen Idec plans to focus on licensing deals rather than mergers to grow its pipeline going forward, Executive VP-Business Development Mark Wiggins said during the company's analyst day Nov. 30